Hydrocodone 3.75 mg is approximately 25% more potent than codeine 30 mg
Based on standardized opioid conversion tables, codeine 30 mg converts to approximately 4.5 morphine milligram equivalents (MME), while hydrocodone 3.75 mg converts to approximately 3.75 MME. This means these doses are nearly equipotent, with hydrocodone 3.75 mg delivering roughly 83% of the analgesic effect of codeine 30 mg when using strict conversion mathematics. However, clinical evidence suggests hydrocodone may provide superior analgesia in practice.
Standardized Conversion Data
The most authoritative conversion factors come from the 2022 CDC Opioid Prescribing Guideline 1 and 2025 NCCN Cancer Pain Guidelines 2:
- Codeine conversion factor: 0.15 (meaning 30 mg codeine = 4.5 MME)
- Hydrocodone conversion factor: 1.0 (meaning 3.75 mg hydrocodone = 3.75 MME)
Using these standardized conversions:
- Codeine 30 mg = 4.5 MME
- Hydrocodone 3.75 mg = 3.75 MME
- Ratio: Hydrocodone 3.75 mg provides approximately 83% of the MME dose of codeine 30 mg
Clinical Efficacy Evidence
Despite similar MME calculations, clinical trials demonstrate hydrocodone combinations may provide superior analgesia to codeine combinations at standard doses. A 1991 randomized trial found that hydrocodone 5 mg/acetaminophen 500 mg resulted in significantly fewer treatment failures compared to codeine 30 mg/acetaminophen 500 mg (0 vs 6 patients, P<0.05), despite similar pain scores 3. Patients receiving hydrocodone also experienced significantly fewer CNS side effects (6 vs 16 patients, P<0.005).
A 1994 postoperative pain study comparing hydrocodone 7.5 mg/acetaminophen 500 mg to codeine 30 mg/acetaminophen 300 mg found the hydrocodone combination significantly superior for total pain relief 4. The hydrocodone effect persisted for 6 hours versus 5 hours for codeine.
However, a 2014 emergency department trial found no clinically significant difference between hydrocodone 5 mg/acetaminophen 500 mg and codeine 30 mg/acetaminophen 300 mg for acute extremity pain, with both reducing pain scores by approximately 50% 5.
Important Clinical Considerations
Codeine's efficacy is highly variable due to CYP2D6 polymorphisms 6. Approximately 10% of Caucasians are poor metabolizers who cannot convert codeine to morphine, rendering it ineffective. Conversely, ultra-rapid metabolizers may experience toxicity. Hydrocodone does not have this same genetic variability issue, as it is primarily metabolized by CYP3A4 to norhydrocodone 7.
The 2013 Emergency Department Analgesia Guidelines recommend NSAIDs over codeine-acetaminophen combinations (weak recommendation, moderate quality evidence) 6, noting that NSAIDs have superior numbers needed to treat (2.7 for naproxen vs 4.4 for codeine-acetaminophen) and fewer CNS depressant effects.
Practical Dosing Context
Standard formulations provide:
- Codeine: typically 30 mg per dose (combined with acetaminophen 300 mg) 2
- Hydrocodone: typically 5-10 mg per dose (combined with acetaminophen 325 mg) 7
Your comparison of hydrocodone 3.75 mg represents a sub-therapeutic dose not commercially available. The lowest FDA-approved hydrocodone formulation is 2.5 mg/acetaminophen 325 mg 1, designed for patients requiring additional caution (elderly, renal/hepatic insufficiency).
For opioid-naïve patients, the CDC recommends starting doses of 20-30 MME/day 1, which would translate to either codeine 30 mg or hydrocodone 5 mg as reasonable starting points, not hydrocodone 3.75 mg.